ClinicalTrials.gg
RecruitingNCT07733765Updated Oct 26, 2026

A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

A Phase 3 interventional study of Ritlecitinib 100 mg and Ritlecitinib 50 mg in Alopecia Areata, sponsored by Pfizer. Recruiting at 38 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 26, 2026First sites in China and South KoreaSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Alopecia Areata by Pfizer — 4 open to participants now, 8 under way, 4 of them phase 3. Alopecia Areata · Pfizer.

Planned enrollment
4th of 10
336 · median 175
Started
2026
with 1 other
Phase 3
5 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Alopecia Areata by Pfizer, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 3, and was the 16th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

4 of the 17 studies in Alopecia Areata by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alopecia Areata by Pfizer, or all of them as a file.
02

Study summary

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).

This study is seeking participants who are

  • 12 years or older (if permitted by the local IRB/EC and local regulatory health authority)
  • have AA with patchy hair loss. The current episode of hair loss has lasted for 6 months or longer but 10 years or less
  • do not have any other diseases or conditions affecting hair loss.

Participants will have a 2 in 3 chance of receiving ritlecitinib 50 mg and a 1 in 3 chance of receiving placebo. The placebo looks like the study medicine but does not contain any active ingredients. Participants will not know what you have been assigned to receive. They will take ritlecitinib or placebo once daily by mouth at home for 24 weeks (6 months). After 24 weeks, the assigned treatment may stay the same or be changed to ritlecitinib 50 mg or 100 mg. This change will depend on how participants' alopecia areata responds to the treatment. Participants will receive the newly assigned treatment for another 23 weeks.

About 4 weeks after the last dose, there will be a follow-up visit. At this visit, the team will check on your health. Participants will take part in this study for about 57 weeks. During this time, they will have study visits at the study clinic. Some study checks will be done by phone.

We will compare the experiences of people receiving ritlecitinib to those of people who do not. This will help us determine if ritlecitinib is safe and effective.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • 18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to \<18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled
  • Have a clinical diagnosis of AA with no other etiology of hair loss.
  • Have >20% to \<50% hair loss of the scalp, as measured by SALT.
  • Current AA episode of hair loss ≥6 months and ≤10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches).

Key Exclusion Criteria

1. Diseases or conditions affecting hair loss, including:

  • Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded.
  • Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).
  • Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    Ritlecitinib 50 milligrams (mg)

    Participants will receive 1 ritlecitinib 50 mg capsule QD orally from Day 1 to Week 24. At Week 24: Responders will be allocated to the below: Arm 1A (Ritlecitinib 50 mg R Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Non-Responders will be re-randomized to either of the below: Arm 1B (Ritlecitinib 50 mg NR→50 mg Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Arm 1C (Ritlecitinib 50 mg NR→100 mg Group): 1 ritlecitinib 100 mg capsule QD and 1 placebo 50 mg capsule QD orally through Week 48.

    Drug: Ritlecitinib 100 mg · Drug: Ritlecitinib 50 mg

  • Placebo comparator
    Placebo

    Participants will receive 1 placebo 50 mg capsule QD orally from Day 1 to Week 24 At Week 24: Responders will be allocated to the below: Arm 2A (Placebo R Group): 1 placebo 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48. Non-Responders will be allocated to the below: Arm 2B (Placebo NR→Ritlecitinib 50 mg Group): 1 ritlecitinib 50 mg capsule QD and 1 placebo 100 mg capsule QD orally through Week 48.

    Drug: Ritlecitinib 100 mg · Drug: Ritlecitinib 50 mg · Other: Placebo

Interventions

  • 100 mg capsule taken orally once daily

  • 50 mg capsule taken orally once daily

  • OtherPlacebo

    Capsule matching either 50mg or 100 mg ritlecitinib capsule taken orally once daily

06

What researchers measure

Primary outcomes

  1. Difference in the proportion of Severity of Alopecia Tool (SALT) 0 responders at Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Week 24

Secondary outcomes

  1. Difference in the proportion of SALT ≤5 responders at Week 24 between ritlecitinib 50 mg QD versus

    Time frame: Week 24

  2. Difference in the proportion of SALT ≤10 responders at Week 24 between ritlecitinib 50 mg QD versus

    Time frame: Week 24

  3. Difference in the proportion of SALT 75 responders at Week 24 between ritlecitinib 50 mg QD versus

    Time frame: Week 24

  4. Difference in the proportion of SALT 90 responders at Week 24 between ritlecitinib 50 mg QD versus

    Time frame: Week 24

  5. Difference in the mean change from baseline (CFB) in SALT score at applicable timepoints through Week 24 for ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18 and 24

  6. Difference in the proportion of Patient Global Impression of Change (PGI-C) responders at Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Week 24

  7. Difference in the proportion of SALT 0 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  8. Difference in the proportion of SALT ≤10 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  9. Difference in the proportion of SALT ≤5 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  10. Difference in the proportion of SALT 75 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  11. Difference in the proportion of SALT 90 responders at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  12. Difference in the mean CFB in SALT score at applicable timepoints between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  13. Difference in the proportion of Eyebrow Assessment (EBA) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  14. Difference in the proportion of Eyelash Assessment (ELA) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  15. Difference in the proportion of PGI-C responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18

  16. Difference in the proportion of Patient's Satisfaction with Hair Growth (P-SAT) responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  17. Difference in the proportion of Improvement in hair loss on each of the Alopecia Areata Patient Priority Outcomes (AAPPO) items 1-4 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  18. Difference in the proportion of Improvement in Emotional Symptoms on each of the AAPPO items 5-8 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  19. Difference in the proportion of Improvement in Activity Limitations on each of the AAPPO items 9-11 responders at applicable timepoints through Week 24 between ritlecitinib 50 mg QD versus placebo

    Time frame: Weeks 8, 12, 18, 24

  20. Proportion of participants with treatment emergent AEs, SAEs, and adverse events leading to discontinuation including those collected during the safety follow-up period

    Time frame: Screening to Follow up period (up to week 57)

  21. Proportion of responders for SALT 0 at appliable timepoints after Week 24

    For each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  22. Proportion of responders for SALT ≤10 at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  23. Proportion of responders for SALT ≤5 at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  24. Proportion of responders for SALT 75 at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  25. Proportion of responders for SALT 90 at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  26. Difference in the proportion of SALT 0 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  27. Difference in the proportion of SALT≤10 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  28. Difference in the proportion of SALT≤5 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  29. Difference in the proportion of SALT75 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  30. Difference in the proportion of SALT90 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  31. Mean CFB in SALT score at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  32. Difference in the mean CFB in SALT score at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  33. Proportion of responders for EBA at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  34. Proportion of responders for ELA at appliable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  35. Difference in the proportion of EBA responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  36. Difference in the proportion of ELA responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  37. Proportion of PGI-C responders at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  38. Proportion of P-Sat responders at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  39. Proportion of responders for Improvement in hair loss on each of the AAPPO items 1-4 at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  40. Proportion of responders for Improvement in Emotional Symptoms on each of the AAPPO items 5-8 at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  41. Proportion of responders for Improvement in Activity Limitations on each of the AAPPO items 9-1 1 responders at applicable timepoints after Week 24

    for each of the 5 groups (Ritlecitinib 50 mg Responder (R) Group, Ritlecitinib 50 mg NR→50 mg Group, Ritlecitinib 50 mg NR→100 mg Group, Placebo NR→Ritlecitinib 50 mg Group, Placebo R Group)

    Time frame: Weeks 28, 36, and 48

  42. Difference in the proportion of PGI-C responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  43. Difference in the proportion of P-SAT responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  44. Difference in the proportion of Improvement in hair loss on each of the AAPPO items 1-4 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  45. Difference in the proportion of Improvement in Emotional Symptoms on each of the AAPPO items 5-8 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  46. Difference in the proportion of Improvement in Activity Limitations on each of the AAPPO items 9-11 responders at applicable timepoints after Week 24 between Ritlecitinib 50 mg NR→50 mg Group and Ritlecitinib 50 mg NR→100 mg Group

    Time frame: Weeks 28, 36, and 48

  47. Proportion of participants with clinically significant abnormalities in clinical laboratory test values including those collected during the safety follow-up period

    Time frame: Screening to Follow up period (up to 57 weeks)

07

Study locations

30 of 38 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 20 months after the start.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 29, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Apr 26, 2028
CompletionEst.
Apr 26, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added, 1 site removed — first sites in China and South Korea. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • California Dermatology & Clinical Research Institute · Encinitas, United StatesNot yet recruiting→Recruiting
  • Clinical and Translational Research Center (CTRC) · Chapel Hill, United StatesNot yet recruiting→Recruiting
  • UNC Dermatology and Skin Cancer Center · Chapel Hill, United StatesNot yet recruiting→Recruiting
  • Bexley Dermatology Research · Bexley, United StatesNot yet recruiting→Recruiting
  • NW Dermatology Institute · Portland, United StatesNot yet recruiting→Recruiting
  • Center for Clinical Studies, LTD. LLP · Houston, United StatesNot yet recruiting→Recruiting
  • Centre de Recherche Saint-Louis (Québec) · Québec, CanadaNot yet recruiting→Recruiting
  • Hospital of the University of Occupational and Environmental Health, Japan · Kitakyushu-shi, JapanNot yet recruiting→Recruiting
Show 19 added (5 United States, 5 Japan, 4 Canada, 3 South Korea, 2 China)
  • Cutaneous Translational Research Program, Johns Hopkins University School of Medicine · Baltimore, United States
  • Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS) · Boston, United States
  • Audiology & Hearing Services · Charlotte, United States
  • Carolinas Imaging Service · Charlotte, United States
  • Darst Dermatology · Charlotte, United States
  • Wiseman Dermatology Research Inc. · Winnipeg, Canada
  • The Centre for Clinical Trials · Oakville, Canada
  • Research Toronto · Toronto, Canada
  • Centre de Recherche Saint-Louis (Montréal) · Montreal, Canada
  • Beijing Friendship Hospital · Beijing, China
  • Huashan Hospital, Fudan University · Shanghai, China
  • Hamamatsu University Hospital · Hamamatsu, Japan
  • Juntendo Tokyo Koto Geriatric Medical Center · Koto-ku, Japan
  • Kyorin University Hospital · Mitaka, Japan
  • Tokyo Medical University Hospital · Shinjuku-ku, Japan
  • Osaka Metropolitan University Hospital · Osaka, Japan
  • Jeonbuk National University Hospital · Jeonju, South Korea
  • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
  • Seoul National University Hospital · Seoul, South Korea
Show 1 removed
  • Cutaneous Translational Research Program (CTReP) · Baltimore, United States
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    19 sites added, 1 site removed — first sites in China and South Korea. 8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • California Dermatology & Clinical Research Institute · Encinitas, United StatesNot yet recruiting→Recruiting
    • Clinical and Translational Research Center (CTRC) · Chapel Hill, United StatesNot yet recruiting→Recruiting
    • UNC Dermatology and Skin Cancer Center · Chapel Hill, United StatesNot yet recruiting→Recruiting
    • Bexley Dermatology Research · Bexley, United StatesNot yet recruiting→Recruiting
    • NW Dermatology Institute · Portland, United StatesNot yet recruiting→Recruiting
    • Center for Clinical Studies, LTD. LLP · Houston, United StatesNot yet recruiting→Recruiting
    • Centre de Recherche Saint-Louis (Québec) · Québec, CanadaNot yet recruiting→Recruiting
    • Hospital of the University of Occupational and Environmental Health, Japan · Kitakyushu-shi, JapanNot yet recruiting→Recruiting
    Show 19 added (5 United States, 5 Japan, 4 Canada, 3 South Korea, 2 China)
    • Cutaneous Translational Research Program, Johns Hopkins University School of Medicine · Baltimore, United States
    • Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS) · Boston, United States
    • Audiology & Hearing Services · Charlotte, United States
    • Carolinas Imaging Service · Charlotte, United States
    • Darst Dermatology · Charlotte, United States
    • Wiseman Dermatology Research Inc. · Winnipeg, Canada
    • The Centre for Clinical Trials · Oakville, Canada
    • Research Toronto · Toronto, Canada
    • Centre de Recherche Saint-Louis (Montréal) · Montreal, Canada
    • Beijing Friendship Hospital · Beijing, China
    • Huashan Hospital, Fudan University · Shanghai, China
    • Hamamatsu University Hospital · Hamamatsu, Japan
    • Juntendo Tokyo Koto Geriatric Medical Center · Koto-ku, Japan
    • Kyorin University Hospital · Mitaka, Japan
    • Tokyo Medical University Hospital · Shinjuku-ku, Japan
    • Osaka Metropolitan University Hospital · Osaka, Japan
    • Jeonbuk National University Hospital · Jeonju, South Korea
    • Kyung Hee University Hospital at Gangdong · Seoul, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    Show 1 removed
    • Cutaneous Translational Research Program (CTReP) · Baltimore, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07733765
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 30, 2026
Primary completion
Apr 26, 2028 (estimated)
Completion
Apr 26, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion